Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
See AW, Conway P, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Pranavan G, Peters J, Smyth LML, Gwini SM, McKenzie DP, Bowden P.
See AW, et al. Among authors: mckenzie dp.
Int J Cancer. 2024 Oct 1;155(7):1248-1256. doi: 10.1002/ijc.35052. Epub 2024 Jun 19.
Int J Cancer. 2024.
PMID: 38898626
Clinical Trial.